person
as of 2026-07-01John Krystal, MD
at a glance
Roles: Principal Investigator, Author
KOL signal score 8
2 publications · 2 high-value
Cross-drug reach: 2 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Yale University
Roles
Principal Investigator, Author
KOL signal
8
Publications
2 (2 high-value)
Trial investigator
no
Publishes on
2 drugs
Trials led
1
A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia
NCT04457310Phase 2Completed
Publications & congress
2
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial.
Lancet (London, England) · 2022 · high-value
A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.
The New England journal of medicine · 2020 · high-value
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
drug
drug
PRINCIPAL_INVESTIGATOR